TAFII-28 Inhibitors

Triptolide inhibits the transcriptional activity of RNA polymerase II, which is essential for the transcription of TATA Box Binding Protein (TBP)-Associated Factor, 28kDa (TAFII-28). By impeding this polymerase, Triptolide can prevent the transcriptional initiation and elongation processes that TAFII-28 is involved in, leading to its functional inhibition.

α-Amanitin binds strongly to RNA polymerase II, which is directly involved in mRNA synthesis where TAFII-28 plays a crucial role. This binding obstructs the polymerase's progression along DNA, thereby functionally inhibiting the transcription process in which TAFII-28 is essential.

DrB inhibits RNA polymerase II transcription, which is necessary for the function of TAFII-28 as a transcription factor. By preventing the phosphorylation of the C-terminal domain of the largest subunit of RNA polymerase II, DrB can thus impede the transcriptional activity in which TAFII-28 is involved, resulting in its functional inhibition.

Actinomycin D intercalates into DNA, preventing the transcription by RNA polymerase, where TAFII-28 is necessary for the formation of the transcription initiation complex. The intercalation blocks the elongation phase of transcription, thereby inhibiting the function of TAFII-28 as it cannot partake in the transcription process.

ICRF-193 is a topoisomerase II inhibitor which interferes with the enzyme's DNA strand passage step, a process required for transcription. As TAFII-28 functions as part of the transcription machinery, its activity relies on the proper configuration of DNA topology that topoisomerase II modifies. ICRF-193's inhibition of this enzyme can subsequently inhibit TAFII-28 function.

Flavopiridol inhibits Cyclin-dependent kinases (CDKs), which are necessary for the phosphorylation of the RNA polymerase II C-terminal domain, an essential step in initiating transcription where TAFII-28 has its role. By inhibiting CDKs, Flavopiridol indirectly prevents the transcriptional activity necessary for TAFII-28's function.

Camptothecin inhibits topoisomerase I, which is responsible for relieving torsional strain in DNA during transcription, a process TAFII-28 is involved in. Inhibition by Camptothecin traps the topoisomerase I-DNA complex, leading to DNA damage and inhibition of the transcription process, thus indirectly inhibiting TAFII-28 function.

Betulinic Acid has been shown to inhibit the activity of HIV-1 Tat-mediated transcription, which involves the recruitment of TAFII-28. By inhibiting this transcriptional activation, Betulinic Acid can functionally inhibit the activity of TAFII-28 in this context.

Chetomin disrupts the structure of the transcription factor complex by ejecting the CHD1 protein from chromatin. As TAFII-28 is a part of the transcription initiation complex, its function relies on the proper assembly of this complex. By disrupting it, Chetomin can indirectly inhibit the functional activity of TAFII-28.

Arcyriaflavin A is a CDK inhibitor, and by inhibiting CDKs, it can prevent the phosphorylation of the RNA polymerase II C-terminal domain. This phosphorylation is crucial for transcription initiation and elongation processes in which TAFII-28 is involved, so inhibition by Arcyriaflavin A indirectly leads to functional inhibition of TAFII-28.